Antifungal Agents

Correct Answer

C — Fluconazole

Rationale

Fluconazole is a triazole antifungal, a subclass of the azole family defined by a five-membered ring containing three nitrogen atoms. The triazoles are preferred over imidazoles for systemic use because of greater selectivity for fungal cytochrome P450 51 over mammalian cytochrome P450 enzymes. Amphotericin B is a polyene antifungal that acts by binding ergosterol in the fungal membrane. Caspofungin is an echinocandin that inhibits fungal cell wall synthesis. Terbinafine is an allylamine that inhibits squalene epoxidase in the ergosterol biosynthesis pathway.

Correct Answer

D — Itraconazole

Rationale

Itraconazole is classified as the broadest-spectrum azole among the options listed. Its spectrum covers Candida species, Aspergillus species, the endemic dimorphic fungi (Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Sporothrix schenckii), and dermatophytes. Fluconazole has a narrower spectrum — it covers Candida species and Cryptococcus neoformans but lacks reliable activity against Aspergillus and dimorphic fungi, and has no role in dermatophyte infections. Clotrimazole is an imidazole used topically for superficial infections, with no systemic role and limited spectrum. Ketoconazole is an older imidazole with significant systemic toxicity that has largely been replaced; its spectrum is narrower than itraconazole for endemic mycoses. Itraconazole's broader spectrum is the key categorical distinction between it and fluconazole in standard antifungal pharmacology.

Correct Answer

B — Mucosal candidiasis and maintenance therapy for cryptococcal meningitis

Rationale

Fluconazole is classified as the preferred agent for mucosal candidiasis — including oropharyngeal, esophageal, and vaginal candidiasis — and for maintenance (secondary prophylaxis) therapy in cryptococcal meningitis after induction with amphotericin B plus flucytosine. These two indications define fluconazole's standard clinical role. Fluconazole is not used for invasive aspergillosis — Aspergillus species are outside its spectrum. It is not used for dermatophyte infections; itraconazole and terbinafine are preferred for those. Histoplasmosis is an indication for itraconazole, not fluconazole, and mucormycosis requires amphotericin B-based therapy. Fluconazole is not recommended for Aspergillus prophylaxis in high-risk transplant patients because it lacks mold coverage; posaconazole or voriconazole are used in that setting.

Correct Answer

B — Itraconazole oral solution

Rationale

The itraconazole oral solution uses hydroxypropyl-beta-cyclodextrin as its solubilizing vehicle. This cyclodextrin carrier substantially improves dissolution and absorption compared to the capsule formulation and makes the oral solution far less dependent on gastric acidity. The itraconazole capsule does not contain a cyclodextrin vehicle; it relies on an acidic gastric environment and the presence of food for adequate dissolution. An intravenous itraconazole formulation does exist using a different cyclodextrin vehicle, sulfobutylether-beta-cyclodextrin, which is the same vehicle used in intravenous voriconazole. There is no lipid complex formulation of itraconazole.

Correct Answer

A — Fluconazole

Rationale

Fluconazole 150 mg as a single oral dose is the standard classified treatment for uncomplicated vulvovaginal candidiasis and is among the most widely used oral antifungal regimens. The single-dose classification reflects fluconazole's reliable oral absorption and pharmacokinetic profile that allows adequate tissue concentrations to persist in the vaginal mucosa from a single administration. Itraconazole is not approved or classified for single-dose oral treatment of vaginal candidiasis; its use for superficial candidal infections requires multi-day courses. Voriconazole and posaconazole are newer triazoles classified primarily for invasive fungal infections in immunocompromised patients and are not approved or used as single-dose treatments for uncomplicated mucosal candidiasis.

Correct Answer

A — Clotrimazole

Rationale

Clotrimazole is an imidazole antifungal, defined by a five-membered ring containing two nitrogen atoms. Imidazoles are used primarily in topical preparations because they lack the selectivity for fungal cytochrome P450 over mammalian cytochrome P450 enzymes that the triazoles provide, making systemic use poorly tolerated. Fluconazole, itraconazole, and voriconazole are all triazoles, characterized by a five-membered ring with three nitrogen atoms. The triazole nitrogen configuration confers greater selectivity for fungal cytochrome P450 51 and is the basis for the entire class of systemically used azole antifungals.

Correct Answer

B — Depletion of ergosterol and accumulation of toxic 14-alpha-methyl sterol intermediates

Rationale

Azole inhibition of cytochrome P450 51 blocks the oxidative removal of the 14-alpha-methyl group from lanosterol, a required step in ergosterol synthesis. This produces two simultaneous consequences: depletion of ergosterol, which is essential for normal membrane fluidity and enzyme function, and accumulation of 14-alpha-methylfecosterol and other toxic sterol intermediates that further disrupt membrane integrity. Together, these effects impair fungal membrane function and arrest growth, producing fungistatic rather than fungicidal activity against most target organisms. Squalene accumulation is associated with allylamine antifungals such as terbinafine, which act earlier in the pathway at squalene epoxidase. Chitin and beta-1,3-d-glucan are cell wall components, not targets of azole action. Acetyl-CoA and mevalonate pathway intermediates are far upstream of the azole target.

Correct Answer

D — Fungistatic activity arrests growth without killing organisms, requiring host immunity for elimination, which is inadequate where rapid fungicidal killing is necessary to reduce early mortality

Rationale

Azoles are fungistatic — they impair fungal growth and replication by depleting ergosterol but do not produce the rapid membrane disruption that kills fungi directly. In cryptococcal meningitis, induction therapy aims to reduce the fungal burden in the cerebrospinal fluid rapidly, because high fungal burden correlates directly with early mortality. This requires fungicidal activity, which azoles cannot provide as monotherapy. Amphotericin B combined with flucytosine is the preferred induction regimen because this combination produces fungicidal killing far more rapidly than azoles alone. Fluconazole does penetrate the blood-brain barrier well, achieving cerebrospinal fluid concentrations of 60 to 80 percent of plasma. Cryptococcus neoformans is not intrinsically resistant to azoles — fluconazole is used in consolidation and maintenance phases where fungistatic activity is sufficient because the fungal burden has already been substantially reduced by induction therapy.

Correct Answer

A — Oral bioavailability of approximately 90 percent, unaffected by gastric acidity, food, or proton pump inhibitors

Rationale

Fluconazole has oral bioavailability of approximately 90 percent and absorption is not affected by gastric acid, food, or gastric motility. This makes it highly reliable in patients receiving proton pump inhibitors, those with achlorhydria, or those who have undergone gastrointestinal surgery — situations where itraconazole capsule absorption falls dramatically. The reliable oral bioavailability also means transition from intravenous to oral fluconazole at equivalent doses is appropriate as soon as oral intake is possible. The profile in option B describes what would be required for itraconazole capsules. The approximately 55 percent bioavailability improved by fatty food describes itraconazole capsules under optimal conditions. Fluconazole does not have reduced bioavailability with proton pump inhibitors.

Correct Answer

B — Excellent central nervous system penetration; enabled by low plasma protein binding that produces a high free drug fraction

Rationale

Fluconazole achieves excellent central nervous system penetration — cerebrospinal fluid concentrations are a high fraction of plasma concentrations, far exceeding most other antifungals and supporting its role in cryptococcal meningitis consolidation therapy. The primary reason is its low plasma protein binding, which keeps a large fraction of circulating drug in the free (unbound) form. Only free drug crosses the blood-brain barrier and distributes into the cerebrospinal fluid; highly protein-bound drugs are largely retained in the vascular compartment and show poor central nervous system penetration. By contrast, amphotericin B has very poor central nervous system penetration, explained by its high protein binding and large molecular size. Fluconazole does not rely on active transport across the blood-brain barrier, and its central nervous system penetration is not attributable to lipophilicity — itraconazole is far more lipophilic than fluconazole but has poorer central nervous system penetration because of its high protein binding.

Correct Answer

B — The dose should be reduced by 50 percent because fluconazole is excreted predominantly unchanged in the urine

Rationale

Fluconazole is excreted approximately 80 percent unchanged in the urine through renal elimination. When creatinine clearance falls below 50 mL/min, the dose should be reduced by 50 percent to prevent drug accumulation. Supplemental doses are also needed after hemodialysis sessions because dialysis removes approximately half the drug. This contrasts with itraconazole, which is extensively metabolized by hepatic cytochrome P450 3A4 and does not require renal dose adjustment. Fluconazole oral bioavailability remains approximately 90 percent regardless of renal function — it is not affected by reduced renal clearance. The dose is reduced, not increased, when creatinine clearance is impaired.

Correct Answer

D — Itraconazole capsule dissolution requires an acidic gastric environment, and omeprazole raises gastric pH and eliminates the acidity needed for adequate dissolution

Rationale

The itraconazole capsule requires an acidic gastric environment and the presence of food for adequate dissolution and absorption. Proton pump inhibitors such as omeprazole raise gastric pH, which dramatically reduces capsule dissolution and can reduce absorption to near zero in some patients. When a patient requires itraconazole and cannot avoid acid-suppressing therapy, the oral solution using hydroxypropyl-beta-cyclodextrin as its vehicle is far less sensitive to gastric pH and is the preferred formulation. Omeprazole does not inhibit cytochrome P450 3A4 — it inhibits cytochrome P450 2C19. Chelation and accelerated motility are not mechanisms of this interaction.

Correct Answer

C — Upregulation of drug efflux pumps that export azoles from the fungal cell, and mutations in the target enzyme that reduce azole binding affinity

Rationale

The two primary mechanisms of acquired azole resistance in Candida species are efflux pump upregulation and target enzyme alteration. Efflux pumps — which belong to two distinct transporter families — actively export azoles out of the fungal cell before they can accumulate to inhibitory concentrations. When efflux pumps are overexpressed, intracellular azole concentrations remain too low to inhibit the target enzyme. The second mechanism involves mutations in cytochrome P450 51, the azole target enzyme (lanosterol 14-alpha-demethylase), that reduce the enzyme's affinity for azoles without eliminating its ability to carry out ergosterol synthesis. Both mechanisms can occur simultaneously in a single organism and together are responsible for most clinically significant azole resistance. Cell wall thickening, enzymatic drug inactivation, and cholesterol substitution are not recognized primary mechanisms of azole resistance in Candida. Alternative sterol pathway induction is not the operative mechanism — ergosterol depletion through target mutation, not pathway bypass, is what occurs.

Correct Answer

C — Fluconazole inhibits cytochrome P450 2C9, reducing clearance of S-warfarin, the more pharmacologically active enantiomer

Rationale

Fluconazole is a potent inhibitor of cytochrome P450 2C9, which is responsible for metabolizing S-warfarin, the more pharmacologically active enantiomer. Inhibition of this metabolic pathway reduces S-warfarin clearance, elevating plasma concentrations and the international normalized ratio substantially — increases of two to three-fold have been reported within days of initiating fluconazole. International normalized ratio monitoring within three to five days of starting fluconazole is required in any patient receiving warfarin, and proactive warfarin dose reductions guided by international normalized ratio response are typically needed. Protein binding displacement is not the mechanism of this interaction. Fluconazole does not induce cytochrome P450 3A4 and does not directly inhibit vitamin K epoxide reductase.

Correct Answer

A — Itraconazole inhibits both cytochrome P450 3A4 and intestinal P-glycoprotein, simultaneously reducing tacrolimus metabolism and increasing its oral absorption

Rationale

Tacrolimus is metabolized by cytochrome P450 3A4 in the intestinal wall and liver, and is a substrate of P-glycoprotein, which limits its oral bioavailability by pumping drug back into the intestinal lumen during absorption. Itraconazole inhibits both of these systems simultaneously: cytochrome P450 3A4 inhibition slows tacrolimus metabolism and raises systemic concentrations, while P-glycoprotein inhibition in the intestinal wall increases tacrolimus absorption from the gut. Together these effects can raise tacrolimus trough concentrations many-fold above the therapeutic range, causing the nephrotoxicity and neurotoxicity seen here. When itraconazole is added to a tacrolimus-based regimen, proactive dose reduction of tacrolimus is required before the first itraconazole dose is given, with daily trough monitoring until new steady state is achieved. Cytochrome P450 2C9 is not the relevant elimination pathway for tacrolimus. Itraconazole is an inhibitor of cytochrome P450 3A4, not an inducer. Renal tubular secretion is not a significant pathway for tacrolimus elimination.

Correct Answer

B — Candida krusei has intrinsic resistance to fluconazole and must never be treated with it regardless of susceptibility testing results

Rationale

Candida krusei has intrinsic resistance to fluconazole due to the combination of low-affinity cytochrome P450 51 and constitutively active efflux pumps. This resistance is not acquired — it is present in every isolate of the species regardless of prior azole exposure. Fluconazole must never be used for Candida krusei infections regardless of susceptibility testing results; a susceptible result from an automated system for this species should be disregarded. An echinocandin is the appropriate treatment. Species-level identification is therefore mandatory before relying on fluconazole for any Candida bloodstream infection. Fluconazole oral bioavailability is approximately 90 percent and is not reduced in neutropenic patients. Fungistatic activity does not absolutely preclude use in bloodstream infections — the key issue here is intrinsic resistance, not pharmacodynamic class.

Correct Answer

C — Reduce the warfarin dose proactively and monitor the international normalized ratio within three to five days of starting fluconazole

Rationale

Fluconazole is a potent inhibitor of cytochrome P450 2C9, which metabolizes S-warfarin, the pharmacologically active enantiomer. This interaction substantially reduces warfarin clearance and can raise the international normalized ratio two to three-fold within days of starting fluconazole — a clinically dangerous rise in a patient with a mechanical valve who depends on stable anticoagulation. The correct management is to anticipate the interaction: reduce the warfarin dose proactively before or at the time fluconazole is initiated, and check the international normalized ratio within three to five days to guide further dose adjustment. Waiting until the end of a 14-day course to check the international normalized ratio risks serious bleeding from sustained supratherapeutic anticoagulation. Discontinuing warfarin entirely is dangerous in a patient with a mechanical heart valve, where therapeutic anticoagulation is mandatory to prevent valve thrombosis and stroke. Switching to itraconazole is not the solution — itraconazole is not first-line for esophageal candidiasis, and it carries its own significant drug interaction liability through cytochrome P450 3A4 and P-glycoprotein inhibition.

Correct Answer

D — Switch to the itraconazole oral solution, which uses a cyclodextrin vehicle that does not depend on gastric acidity for adequate dissolution and absorption

Rationale

When itraconazole capsule absorption has failed because of elevated gastric pH — established here by an undetectable trough level — the correct management is to switch to the itraconazole oral solution. The oral solution uses hydroxypropyl-beta-cyclodextrin as its solubilizing vehicle, which keeps itraconazole in solution independent of gastric acidity. This formulation achieves reliable absorption even in patients taking proton pump inhibitors and those with achlorhydria. Doubling the capsule dose does not overcome the dissolution failure because the problem is the physical inability of the capsule to dissolve in a low-acid environment, not inadequate dose. Adding an H2 blocker would worsen acid suppression further, not restore it — and in any case a patient already on a proton pump inhibitor would not benefit from adding another acid suppressant. Acidifying the stomach with cola is an anecdotal strategy that is unreliable and not a recognized clinical management approach. The oral solution is the definitive, evidence-based solution when capsule absorption fails in the setting of acid suppression.